| Range: | 0.023-0.121 | Vol Avg: | 655 | Last Div: | 0 | Changes: | -0.02 |
| Beta: | -2.23 | Cap: | 0.01B | Currency: | USD | Exchange: | PNK |
| Sector: | Healthcare | IPO: | Mon Jul 20 2020 | Empoloyees: | 36 | ||
| CUSIP: | CIK: | ISIN: | GB00B0381Z20 | Country: | GB | ||
| CEO: | Mr. Richard Marsden | Website: | https://www.synairgen.com | ||||
SYGGF 0.19 Stock Price Synairgen plc
Synairgen plc discovers and develops drugs for respiratory diseases. It develops SNG001, an inhaled interferon beta for the treatment of COVID-19; inhaled interferon beta (IFN-ß), which is in Phase-II clinical trials for the treatment of asthma caused by the common cold and flu; IFN-ß that is in Phase-II clinical trials for the treatment or prevention of chronic obstructive pulmonary disease; and LOXL2 inhibitor for the treatment of idiopathic pulmonary fibrosis (IPF) disease. The company has a licensing and collaboration agreement with Pharmaxis Ltd. to develop a LOXL2 inhibitor. Synairgen plc was incorporated in 2004 and is headquartered in Southampton, the United Kingdom.
Stock Details
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow